IGI Logo

SUPRIYA Navigates a Challenging Phase, with Sharp Profitability Pressure

We believe SUPRIYA is navigating a challenging phase, with earnings recovery projected to take time. Revenue growth is projected to remain healthy at ~20% in the near term. However, profitability faces significant pressure from incremental cost at the Ambernath facility, regulatory disruption in LatAm and higher raw material cost. The management has revised its EBITDA margin guidance to 23–25%, implying a sharp contraction of ~1,000 bps. We project only a gradual recovery from H2FY28E. Developments in customer contracts at the Ambernath facility also remain a key monitorable. Considering these headwinds, we significantly lower our estimate by 42.4%/30.2% for FY27E/FY28E, respectively. We roll forward our valuation to the average of FY28E–FY29E EPS, arriving at a revised target price of INR 685 and downgrading our rating to ‘REDUCE.’

Earnings Disappoint on Significant Margin Contraction

* Revenue grew 3.2% YoY / 8.7% QoQ to INR 2,063 Mn (vs. CIE estimate of INR 2,198 Mn).

* EBITDA declined 37.5% YoY / 4.3% QoQ to INR 454 Mn; margin contracted 1,435 bps YoY / 300 bps QoQ to 22.0% (vs. CIE estimate of 27.0%).

* PAT declined 42.0% YoY but increased 21.7% QoQ to INR 293 Mn (vs. CIE estimate of INR 400 Mn).

Multiple Operating Headwinds Drive Sharp Margin Contraction

SUPRIYA reported a sharp margin contraction and decline in profitability, reflecting multiple operating challenges:

* LatAm regulatory disruption (~3% impact): Certain high-margin products were newly classified as controlled substances. Import authorisation could take 4–5 months, delaying supplies and affecting revenue.

* Higher input cost (~3% impact): Rising raw material and solvent prices, coupled with delays in passing on cost under existing contracts, weighed on margin.

* Ambernath facility ramp-up (~6% impact): The facility incurred incremental cost of ~INR 600 Mn during the ramp-up phase, adding to the cost base. The management reiterated revenue guidance of ~INR 10,000 Mn but acknowledged significant pressure on profitability, lowering EBITDA margin guidance to 23–25%. We take a more conservative view and project FY27E EBITDA margin at ~21%, down from 35.5% in FY26. While SUPRIYA retains a portfolio of high-margin products, near-term profitability remains exposed to regulatory disruption, elevated input cost and facility ramp-up expenses. We forecast some recovery from H2FY28E, as the Ambernath facility begins contributing revenue and cost pass-throughs commence from Q1FY28E. However, the timing and pace of recovery remain key

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131